Pericapsular Nerve Block Versus Intrathecal Morphine for Analgesia After Primary Hip Arthroplasty
Launched by CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS · Mar 12, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different methods of pain relief for patients undergoing total hip replacement surgery. The researchers want to find out if a technique called the pericapsular nerve block (PENG) is just as effective as using morphine given directly into the spinal fluid (intrathecal morphine) in reducing pain after the surgery. Patients in the trial will be randomly placed into one of two groups: one will receive the PENG block along with a local anesthetic for spinal anesthesia, while the other group will receive a combination of local anesthetic and morphine, along with a fake PENG block to keep the study fair.
To participate in this trial, individuals must be at least 18 years old and scheduled for elective hip replacement surgery. They should be in good overall health (classified as ASA I-III) and able to give consent on their own. However, those with certain health issues, allergies to specific medications, or who are pregnant or breastfeeding will not be eligible. Participants can expect to receive either of the two pain relief methods and will be monitored to see how well each method works in managing their postoperative pain.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male and female patients
- • ASA (American Society of Anaesthesiologists) I-III
- • 18 years of age or older
- • Patients scheduled for elective primary hip arthroplasty
- • Able to give written conformed consent autonomously
- Exclusion Criteria:
- • Refusal or inability to give consent
- • Allergy to any of: ropivacaine, paracetamol, ibuprofen, ketorolac, morphine, ondansetron or dexamethasone
- • Bleeding diathesis
- • Neurological deficit of the operative side
- • Existing preoperative opioid use
- • Renal insufficiency (GFR\<30ml/min according to the Cockroft-Gault formula)
- • Hepatic insufficiency
- • Pregnant or lactating women
About Centre Hospitalier Universitaire Vaudois
The Centre Hospitalier Universitaire Vaudois (CHUV) is a leading academic medical center located in Lausanne, Switzerland, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHUV plays a pivotal role in translating scientific discoveries into transformative therapies, enhancing patient care across a diverse range of medical disciplines. With a multidisciplinary team of experts and state-of-the-art facilities, CHUV is dedicated to fostering collaboration and delivering high-quality evidence that informs clinical practice and policy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lausanne, Vaud, Switzerland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported